<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/206F54F8-2EF5-431C-9C0B-7CC89412CF30"><gtr:id>206F54F8-2EF5-431C-9C0B-7CC89412CF30</gtr:id><gtr:name>CAMBRIDGE BIOMAGNETICS LIMITED</gtr:name><gtr:address><gtr:line1>St John's Innovation Centre</gtr:line1><gtr:line2>Cowley Road</gtr:line2><gtr:postCode>CB4 0WS</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/206F54F8-2EF5-431C-9C0B-7CC89412CF30" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>206F54F8-2EF5-431C-9C0B-7CC89412CF30</gtr:id><gtr:name>CAMBRIDGE BIOMAGNETICS LIMITED</gtr:name><gtr:address><gtr:line1>St John's Innovation Centre</gtr:line1><gtr:line2>Cowley Road</gtr:line2><gtr:postCode>CB4 0WS</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>172567.0</gtr:offerGrant><gtr:projectCost>403100.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7A64772E-B3EF-402E-8843-21B8657F9CDF"><gtr:id>7A64772E-B3EF-402E-8843-21B8657F9CDF</gtr:id><gtr:firstName>Thanos</gtr:firstName><gtr:surname>Mitrelias</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=720064"><gtr:id>8E7F4A5D-828A-4502-A8A4-3FA2E619F936</gtr:id><gtr:title>Magnetic lab-on-chip devices for multiplexed clinical diagnostics</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Development of Prototype</gtr:grantCategory><gtr:grantReference>720064</gtr:grantReference><gtr:abstractText>There is a need of physicians and clinicians to screen biological samples for many pathogens
in a cost effective and reliable way, ideally in a single test (multiplexing). The ability to
quickly and accurately diagnose diseases and their many subtypes (infectious and
autoimmune diseases, cancer) is crucial to provide rapid and targeted treatment to individual
patients. The trend is towards molecular tests which avoid the need of manual microscope
diagnosis of cultured samples as it has been traditionally to date. Conventionally such tests are
sent away to specialist laboratories, however many of the multiplexed tests are best performed
at the point of care (POC), in order to streamline treatment. Simple POC multiplexed assays
for cardiac markers, for example, are used in emergency rooms for early diagnosis of heart
attacks. The addition of more markers to tests would enable better treatment, but the current
technology is limited in multiplexing capabilities. In addition, physicians already run simple
tests for infectious diseases such as Streptococcus in order to provide treatment right away
and prevent further spread. They could do the same for infectious diseases that require
analysis of multiple sequences, such as influenza and MRSA or for diabetes where additional
markers could enable better long-term care, if they had better multiplexing capabilities.
Cambridge BioMagnetics?s (CBM) core technology addresses this business opportunity with
two offerings within the global Healthcare market. The first provides cost effective,
customisable, lab-on-a-chip multiplex diagnostic tools for POC use by doctors, nurses and
even non-specialised staff. This offers Healthcare cost reduction and the patients benefit from
reduced waiting times and elimination of misdiagnosis. The second offering provides
multiplex molecular diagnostics for clinical labs for more specialised tests.</gtr:abstractText><gtr:fund><gtr:end>2014-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2012-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>172567</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">720064</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>